GUANGZHOU, China–(BUSINESS WIRE)–Dec. 01, 2021 LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T[…]
Read more
Category: Biomedical
A Stitch in Time: Taiwan and Japan Join Hands in Providing Critical Care
HSINCHU, Taiwan–(BUSINESS WIRE)–Nov. 25, 2021 Japan has donated five batches of the AZ COVID-19 vaccine to Taiwan, and Taiwan has[…]
Read more
Icure Acquires Drug Product Approval for World’s First Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea
The world’s first donepezil patch is approved for the incrementally modified drug Launching in 2022, its availability will be expanded[…]
Read more
Novel Blood Pressure Stabilization Therapy Presented at Neuroscience 2021
Scientist Grégoire Courtine demonstrated the effectiveness of ARC Therapy during his Presidential Special Lecture EINDHOVEN, Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)–Nov.[…]
Read more
Celltrion’s Monoclonal Antibody Treatment regdanvimab Approved by the European Commission for the Treatment of COVID-19
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following positive opinion by the European Medicines Agency’s (EMA) Committee[…]
Read more
Celltrion receives CHMP positive opinion for regdanvimab (CT-P59) as one of the first monoclonal antibodies recommended as a treatment for COVID-19 by the CHMP
The CHMP positive opinion marks the first time a monoclonal antibody treatment for COVID-19 has received a recommendation for marketing[…]
Read more
Ushering in a New Era of Medical Education at NTHU
HSINCHU, Taiwan–(BUSINESS WIRE)–Oct. 02, 2021 National Tsing Hua University’s plan to establish a post-baccalaureate program in medicine has been approved[…]
Read more
NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device
HSINCHU, Taiwan–(BUSINESS WIRE)–Sep. 24, 2021 As COVID-19 vaccination has raised the issue of thrombosis, Dr. Chih-Kuang Yeh, Distinguished Professor of[…]
Read more
Celltrion’s monoclonal antibody treatment for COVID-19 regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
The approval marks the first time a monoclonal antibody treatment for COVID-19 received full approval to treat patients with COVID-19[…]
Read more
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing Collaboration and RTX-003 License with iBio Inc.
SAN CARLOS, Calif.–(BUSINESS WIRE)–Aug. 25, 2021 RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing[…]
Read more